AEYE Health, Ford Medical partner to expand diabetic eye exam screening solutions to pharmacies

AEYE-DS, AEYE Health’s AI-driven technology, is the first and only FDA-cleared AI solution that’s compatible with a portable camera. Image credit: AdobeStock/Fxquadro

Artificial intelligence (AI)-powered retinal diagnostics AEYE Health and health care distributor Ford Medical have announced a partnership to bring AEYE’s autonomous diabetic eye examination screening solutions to pharmacies and nonacute centers around the nation.¹ These screening solutions will work to make early detection of diabetic retinopathy (DR) easier with on-the-spot screening that is more widely accessible for patients, according to a news release.

“We're excited to collaborate with Ford Medical to bring AEYE-DS into pharmacies and nonacute centers - a strategic step toward making diabetic eye exams more accessible than ever," said Zack Dvey-Aharon, PhD, CEO and cofounder of AEYE Health, in the release. "By integrating fully autonomous AI into everyday care settings, we're making it much easier to detect disease early and prevent blindness for millions at risk."

AEYE-DS, AEYE Health’s AI-driven technology, is the first and only FDA-cleared AI solution compatible with a portable camera. The technology allows for point-of-care screening for patients who may not regularly see an eye care provider or specialist, which enhances care outreach, expands pharmacy services, and creates new revenue opportunities, according to the company.¹ In 5 seconds, the technology analyses the examinations, with 93% sensitivity and 91.4% specificity for diagnosing more-than-mild retinopathy on desktop and between 92% and 93% sensitivity and between 89% and 94% specificity in handheld devices.²

"This partnership with AEYE Health represents a major step forward in making AI-driven diagnostics more accessible," said Scott Greenberg, vice president of sales at Ford Medical, in the release. "We're giving nonacute providers the ability to deliver real clinical value through early detection - keeping patients healthier and helping providers grow their impact and their business."

Specifically, the partnership will allow Ford Medical to distribute AEYE Health’s screening solutions, which will allow pharmacies and acute centers to offer in-house, noninvasive eye examinations that deliver immediate diagnostic results with no specialist needed. The solution is also fully reimbursable under an existing CPT code.¹

AEYE is also developing an AEYE-CS comprehensive screening technology, which is used to diagnose or predict the development of numerous diseases from retinal images, including DR, glaucoma, age-related macular degeneration, diabetes, cataract, diabetic macular edema, cardiovascular disease, occlusion, and hypertension. The device is currently being utilized in investigational use only in the US.³

AEYE-DS can also be utilized in primary care, home care, and teleretinal screening services, in addition to enhancing fundus cameras for camera manufacturers.²

References:

1. AEYE Health and Ford Medical partner to bring fully autonomous, reimbursable AI diabetic eye exam screening solutions to pharmacies. News release. PR Newswire. July 15, 2025. Accessed July 16, 2025. https://www.prnewswire.com/news-releases/aeye-health-and-ford-medical-partner-to-bring-fully-autonomous-reimbursable-ai-diabetic-eye-exam-screening-solutions-to-pharmacies-302505909.html

2. 1-minutes AI diabetic eye exam at any point of care. AEYE Health. Accessed July 16, 2025. https://www.aeyehealth.com/

3. AEYE Comprehensive Screening (AEYE-CS). AEYE Health. Accessed July 16, 2025. https://www.aeyehealth.com/aeye-comprehensive-screening